Danmörk - danska - Lægemiddelstyrelsen (Danish Medicines Agency)

abacus medicine a/s - eng-rottehale - frysetørret tablet - 75.000 sq.t

Danmörk - danska - Lægemiddelstyrelsen (Danish Medicines Agency)

linde sverige ab - nitrogenoxid, oxygen - medicinsk gas, komprimeret - 50+50 %

Danmörk - danska - Lægemiddelstyrelsen (Danish Medicines Agency)

accord healthcare b.v. - mycophenolatmofetil - pulver til koncentrat til infusionsvæske, opløsning - 500 mg

Danmörk - danska - Lægemiddelstyrelsen (Danish Medicines Agency)

septodont ou septodont s.a.s. ou specialites septodont - mepivacainhydrochlorid - injektionsvæske, opløsning - 30 mg/ml

Danmörk - danska - SEGES Landbrug & Fødevarer

bayer a/s - piperonylbutoxid, pyrethrin - flydende middel - 135 g/l piperonylbutoxid ; 30 g/l pyrethrin i og ii

Danmörk - danska - SEGES Landbrug & Fødevarer

cbc (europe) s.r.l. - beauveria - suspensionskoncentrat - 23000000000 cfu/l beauveria bassiana atcc 74040

Evrópusambandið - danska - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastiske midler - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Evrópusambandið - danska - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfom, mantelcelle - antineoplastiske midler - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Evrópusambandið - danska - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - thiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastiske midler - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Evrópusambandið - danska - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - aminosyre-metabolisme, infødte fejl - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.